Questions and answers on the PIP compliance verification procedure at EMA, and on paediatric rewards
European Medicines Agency policy on changes in scope of paediatric investigation plan (PIP) decisions
Ocrevus
Veterinary medicines European public assessment report (EPAR): Stemyca, equine umbilical cord mesenchymal stem cells, Status: Opinion
Veterinary medicines European public assessment report (EPAR): Bovilis Lumpyvax, Lumpy skin disease vaccine (live), Status: Opinion
Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 6-8 October 2026
EMA recommends authorisation of veterinary vaccine for lumpy skin disease in cattle
Human medicines European public assessment report (EPAR): Giapreza, angiotensin II, Date of authorisation: 23/08/2019, Revision: 7, Status: Authorised
21st industry stakeholder platform - operation of European Union (EU) pharmacovigilance, Online, European Medicines Agency, Amsterdam, the Netherlands, from 20 October 2026, 13:00 (CEST) to 20 October 2026, 17:30 (CEST)
Decision of the Management Board amending budget No. 01, amending appropriations in budget 2026 and transfer of appropriations